biogen.com (BIIB) Price-to-Projected Revenue Ratio
Biogen Inc. (BIIB) management is restoring investor confidence following controversial market launches. The forward price-to-sales valuation on the GURU.Markets chart visualizes the results of this strategy, where 0.50 represents the latest metric reading. The growth of the biosimilars portfolio reduces patent risks, although geopolitical fragmentation complicates international biomaterial logistics and the conduct of global clinical trials.
Biogen Idec (BIIB) - metric breakdowns and financial figures
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- company total debt and liquidity indicators:
- financial results and valuation multiples details:
BIIB - Company Profit|Projected Future Earnings Biogen Inc.|BIIB - Market Cap to Earnings|Projected Price to Earnings Biogen Corp|BIIB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Idec|BIIB - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Biogen|BIIB - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth biogen.com|BIIB - Earnings per share growth in current year|Earnings growth forecast for next year Biogen Inc.
- sales and revenue data:
Comprehensive company analysis:Biogen BIIB
To build a defensive portfolio, fundamental screening requires an assessment of market value relative to expected earnings. This metric is calculated as the ratio of the current market capitalization of Biogen Inc. (BIIB) to projected revenue for the following year, excluding quarterly report volatility. Extensive outsourcing of clinical trials and logistics optimizes costs, making the forward price-to-sales ratio a key indicator of capital management efficiency.
Analysis of competing companies
Forward P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|Market Cap to Expected Sales Ratio Regencell Bioscience Ltd (RGC)|AXSM - Price-to-Projected Revenue Ratio|ACAD (ACADIA Corp) - Market Cap to Projected Revenue|XENE: Forward P/S Multiple|Forward Price-to-Revenue Multiple vikingtherapeutics.com|Forward Price-to-Revenue Multiple SUPN|Catalyst Pharma (CPRX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple DNLI|Price-to-Projected Revenue Ratio HRMY (Harmony Corp)|Forward P/S Multiple BHVN (Biohaven Ltd.)|Market Cap to Expected Sales Ratio amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Praxis Precision Medicines Inc PRAX|AVXL: Forward P/S Multiple|CBLL (CeriBell EEG) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Prothena Biosciences|Market Cap to Projected Revenue ALEC (Alector Therapeutics)|Forward P/S Multiple ANNX|OMER - Market Cap to Future Revenue Ratio|Neurogene Corp - Forward Price-to-Revenue Multiple|Forward P/S Multiple AC Immune Inc ACIU|VYGR - Price-to-Projected Revenue Ratio|Forward Price to Sales NMRA (neumoratx.com)|Scilex (SCLX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tevogen Bio Holdings Inc. (TVGN)|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CGTX|Forward P/S Multiple IKT|Market Cap to Expected Sales Ratio cassavasciences.com|Price-to-Projected Revenue Ratio Assertio ASRT|Coya Therapeutics Inc (COYA) - Market Cap to Future Revenue Ratio|VistaGen Therapeutics Inc - Forward P/S Multiple|Projected Price to Revenue Ovid Therapeutics Inc. (OVID)|ABOS: Forward P/S Multiple|Market Cap to Future Revenue Ratio cervomed.com (CRVO)|Price-to-Projected Revenue Ratio Alterity Therapeutics Ltd.|Market Cap to Projected Revenue CLNN (Clene Nanomedicine)|Forward Price-to-Revenue Multiple PEPG (PepGen Inc.)|JUNS (Jupiter Neurosciences, Inc.) - Forward Price to Sales|Forward P/S Multiple RLMD (Relmada Therapeutics)|Market Cap to Expected Sales Ratio annovisbio.com (ANVS)|GRCE - Price-to-Projected Revenue Ratio|AIFF (Firefly Neuroscience, Inc.) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|Forward Price-to-Revenue Multiple NeuroSense Therapeutics Ltd.|Forward Price-to-Revenue Multiple RVPH|MetaVia, Inc. (MTVA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple NRXS|Price-to-Projected Revenue Ratio HSDT (heliusmedical.com)|Forward P/S Multiple PASG (Passage Bio)|Market Cap to Expected Sales Ratio Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - Forward P/S Multiple|Market Cap to Expected Sales Ratio athira.com ATHA|ADXN: Forward P/S Multiple|ALZN (Alzamend Neuro) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Projected Revenue PTIX (Protagenic)|Forward P/S Multiple KTTA|CRGT - Market Cap to Future Revenue Ratio|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Brainstorm Cell Therapeutics Inc. BCLI|CARA - Price-to-Projected Revenue Ratio|Forward Price to Sales CHRO (Chromocell)|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio MRNS|Forward P/S Multiple NKGN|Market Cap to Expected Sales Ratio NeuroBo Pharma|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|synaptogen.com (SNPX) - Market Cap to Future Revenue Ratio|Trevena - Forward P/S Multiple|Projected Price to Revenue Vigil Neuroscience (VIGL)|WENA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
